A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer

Published:2015-11 Issue:6 Volume:16 Page:457-465
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Ellis Peter M.^ORCID,Leighl Natasha B.,Hirsh Vera,Reaume M. Neil,Blais Normand,Wierzbicki Rafal,Sadrolhefazi Behbood,Gu Yu,Liu Dan,Pilz Korinna,Chu Quincy

Funder

Boehringer Ingelheim

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference32 articles.

1. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non–small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial;Dancey;Lung Cancer,2004

2. Erlotinib in previously treated non–small-cell lung cancer;Shepherd;N Engl J Med,2005

3. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Non–small-cell lung cancer. Version 6. 2015. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed April 20, 2015.

4. A randomised phase II study of pemetrexed versus pemetrexed + erlotinib as second-line treatment for locally advanced or metastatic non-squamous non–small-cell lung cancer;Dittrich;Eur J Cancer,2014

5. Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non–small-cell lung cancer: a meta-analysis of 14 randomized controlled trials;Li;Curr Med Res Opin,2014

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spectroscopic study on volasertib: Highly stable complexes with albumin and encapsulation into alginate/montmorillonite bionanocomposites;Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy;2024-12

2. Mitochondrial Signatures Shape Phenotype Switching and Apoptosis in Response to PLK1 and RSK Inhibitors in Melanoma;2024-06-17

3. MYC and HSF1 Cooperate to Drive PLK1 inhibitor Sensitivity in High Grade Serous Ovarian Cancer;2024-06-13

4. The two sides of chromosomal instability: drivers and brakes in cancer;Signal Transduction and Targeted Therapy;2024-03-29

5. The Juxtaposition of Allosteric and Catalytic Inhibition in PLK1: Tradeoff for Chemotherapy and Thermodynamic Profiles of KBJK557 and BI 6727;Journal of Computational Biophysics and Chemistry;2024-01-25